Journal article
Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study
JD Doecke, F Hartnell, P Bampton, S Bell, G Mahy, Z Grover, P Lewindon, LV Jones, K Sewell, K Krishnaprasad, R Prosser, D Marr, J Fischer, GR Thomas, JV Tehan, NS Ding, SE Cooke, K Moss, A Sechi, P De Cruz Show all
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | WILEY-BLACKWELL | Published : 2017
DOI: 10.1111/apt.13880
Abstract
BACKGROUND: Maintenance anti-tumour necrosis factor-α (anti-TNFα) treatment for Crohn's disease is the standard of care for patients with an inadequate response to corticosteroids and immunomodulators. AIM: To compare the efficacy and safety of infliximab and adalimumab in clinical practice and assess the value of concomitant immunomodulator therapy. METHODS: We performed an observational cohort study in consecutive patients with Crohn's disease qualifying for anti-TNFα treatment in Australia and New Zealand between 2007 and 2011. Demographic and clinical data were prospectively recorded to identify independent factors associated with induction and maintenance of response to infliximab or ad..
View full abstractGrants
Funding Acknowledgements
This work was supported by the Royal Brisbane and Women's Hospital Research Foundation, and the ANZ IBD Consortium.